Pancreatic Ductal Adenocarcinoma
Conditions
Keywords
Pancreatic ductal adenocarcinoma, Unresectable pancreatic cancer, Radiofrequency ablation, Endoscopic ultrasound
Brief summary
The clinical application of intraoperative or percutaneous radiofrequency ablation (RFA) for pancreatic ductal adenocarcinoma (PDAC) is limited due to higher mortality and incidence of adverse events. The aim of this study was to evaluate the efficacy and safety of endoscopic ultrasonography-guided RFA (EUS-RFA) for locally advanced, unresectable PDAC. Patients with unresectable PDAC who underwent EUS-RFA were included from September 2013 to June 2016. Pre- and post-procedural clinical data was retrospective collected.
Detailed description
evaluate the efficacy and safety of endoscopic ultrasonography-guided RFA (EUS-RFA) for locally advanced, unresectable PDAC.
Interventions
PROCEDUREEUS-RFA
Use EUS-RFA to treat unresectable pancreatic cancer
Sponsors
First People's Hospital of Hangzhou
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* age 20 to 80 years old. ② unresectable PDAC based on review of abdominal cross-sectional imaging (CT or MRI) and cytology/ histology results. ③Intolerance to chemotherapy due to side effects or patient's comorbidities.
Exclusion criteria
* Pregnancy or breast-feeding；②ECOG performance status 3 or 4；③Patients with distant metastases or malignant ascites, life expectancy less than 3 months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Tumor size | 2 years | Tumor size |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Serum levels of CA19-9 | 2 years | Serum levels of CA19-9 before and after surgery |
| survival rate | 2 years | including Overall survival |
| Adverse events | 2 years | Adverse events |
Countries
China
Outcome results
None listed